In Silico Molecular Dynamics of Griseofulvin and Its Derivatives Revealed Potential Therapeutic Applications for COVID‐19

Abstract

Treatment options for Coronavirus Disease 2019 (COVID‐19) remain limited, and the op-tion of repurposing approved drugs with promising medicinal properties is of increasing interest in therapeutic approaches to COVID‐19. Using computational approaches, we examined griseoful-vin and its derivatives against four key anti‐SARS‐CoV‐2 targets: main protease, RdRp, spike protein receptor‐binding domain (RBD), and human host angiotensin‐converting enzyme 2 (ACE2). Molecular docking analysis revealed that griseofulvin (CID 441140) has the highest docking score (–6.8 kcal/mol) with main protease of SARS‐CoV‐2. Moreover, griseofulvin derivative M9 (CID 144564153) proved the most potent inhibitor with −9.49 kcal/mol, followed by A3 (CID 46844082) with −8.44 kcal/mol against M protease and ACE2, respectively. Additionally, H bond analysis revealed that compound A3 formed the highest number of hydrogen bonds, indicating the strongest inhibitory efficacy against ACE2. Further, molecular dynamics (MD) simulation analysis revealed that griseofulvin and these derivatives are structurally stable. These findings suggest that griseoful-vin and its derivatives may be considered when designing future therapeutic options for SARS‐ CoV‐2 infection.